Israel Englander Bluebird Bio, Inc. Transaction History

Millennium Management LLC

$199 Billion
Q3 2024

A detailed history of Israel Englander (Millennium Management LLC) transactions in Bluebird Bio, Inc. stock. As of the latest transaction made, Millennium Management LLC holds 1,608,793 shares of BLUE stock, worth $13.6 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,608,793

Previous 5,146,653 68.74%

Holding current value

$13.6 Million

Previous $5.04 Million 83.42%

% of portfolio

0.0%

Previous 0.0%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$0.47 - $1.35 $1.66 Million - $4.78 Million	-3,537,860 Reduced 68.74%	1,608,793 $836,000
Q2 2024 Aug 14, 2024	SELL	$0.85 - $1.26 $928,954 - $1.38 Million	-1,092,888 Reduced 17.52%	5,146,653 $5.04 Million
Q1 2024 May 15, 2024	BUY	$0.91 - $1.75 $2.57 Million - $4.95 Million	2,825,929 Added 82.78%	6,239,541 $7.99 Million
Q4 2023 Feb 14, 2024	BUY	$1.32 - $4.83 $4.51 Million - $16.5 Million	3,413,612 New	3,413,612 $4.71 Million
Q1 2023 May 15, 2023	BUY	$3.14 - $8.22 $2.81 Million - $7.37 Million	896,076 Added 123.92%	1,619,161 $5.15 Million
Q4 2022 Feb 14, 2023	SELL	$5.77 - $8.49 $5.33 Million - $7.85 Million	-924,245 Reduced 56.11%	723,085 $5 Million
Q3 2022 Nov 14, 2022	SELL	$3.75 - $7.39 $3.16 Million - $6.22 Million	-841,488 Reduced 33.81%	1,647,330 $10.4 Million
Q2 2022 Aug 15, 2022	BUY	$2.94 - $5.23 $4.6 Million - $8.19 Million	1,566,073 Added 169.72%	2,488,818 $10.3 Million
Q1 2022 May 16, 2022	BUY	$4.07 - $10.6 $1.59 Million - $4.15 Million	391,568 Added 73.72%	922,745 $4.48 Million
Q4 2021 Feb 14, 2022	BUY	$8.96 - $16.31 $2.33 Million - $4.24 Million	259,870 Added 95.78%	531,177 $5.31 Million
Q3 2021 Nov 15, 2021	SELL	$11.24 - $21.0 $1.62 Million - $3.03 Million	-144,056 Reduced 34.68%	271,307 $5.19 Million
Q2 2021 Aug 16, 2021	SELL	$18.04 - $22.09 $470,753 - $576,438	-26,095 Reduced 5.91%	415,363 $13.3 Million
Q1 2021 May 17, 2021	BUY	$16.59 - $33.89 $5.98 Million - $12.2 Million	360,444 Added 444.92%	441,458 $13.3 Million
Q4 2020 Feb 16, 2021	SELL	$27.5 - $37.92 $667,810 - $920,849	-24,284 Reduced 23.06%	81,014 $3.51 Million
Q3 2020 Nov 16, 2020	SELL	$34.44 - $43.75 $3.05 Million - $3.87 Million	-88,527 Reduced 45.67%	105,298 $5.68 Million
Q2 2020 Aug 14, 2020	SELL	$27.12 - $45.97 $7.47 Million - $12.7 Million	-275,522 Reduced 58.7%	193,825 $11.8 Million
Q1 2020 May 14, 2020	BUY	$26.16 - $63.5 $6.03 Million - $14.6 Million	230,515 Added 96.52%	469,347 $21.6 Million
Q4 2019 Feb 14, 2020	BUY	$46.96 - $61.67 $7.88 Million - $10.3 Million	167,795 Added 236.21%	238,832 $21 Million
Q3 2019 Nov 14, 2019	SELL	$59.47 - $93.1 $741,828 - $1.16 Million	-12,474 Reduced 14.94%	71,037 $6.52 Million
Q2 2019 Aug 15, 2019	SELL	$75.84 - $105.21 $12.5 Million - $17.4 Million	-165,423 Reduced 66.45%	83,511 $10.6 Million
Q2 2019 Aug 14, 2019	BUY	$75.84 - $105.21 $8.51 Million - $11.8 Million	112,154 Added 82.0%	248,934 $13.3 Million
Q1 2019 May 14, 2019	BUY	$64.44 - $104.11 $115,540 - $186,669	1,793 Added 1.33%	136,780 $21.5 Million
Q4 2018 Feb 14, 2019	BUY	$59.1 - $93.26 $3.37 Million - $5.32 Million	57,055 Added 73.21%	134,987 $13.4 Million
Q3 2018 Nov 14, 2018	SELL	$88.86 - $117.49 $32.8 Million - $43.3 Million	-368,616 Reduced 82.55%	77,932 $11.4 Million
Q2 2018 Aug 14, 2018	BUY	$99.64 - $127.59 $44.5 Million - $57 Million	446,548 New	446,548 $70.1 Million
Q1 2018 May 15, 2018	SELL	$105.8 - $150.94 $1.55 Million - $2.21 Million	-14,670 Closed	0 $0
Q4 2017 Feb 14, 2018	BUY	$81.25 - $130.7 $1.19 Million - $1.92 Million	14,670	14,670 $2.61 Million

Others Institutions Holding BLUE

# of Institutions

150

Shares Held

63.4M

Call Options Held

264K

Put Options Held

428K

View Full List

About bluebird bio, Inc.

Ticker BLUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,121,800
Market Cap $652M
Description
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell ...

More about BLUE

Track Israel Englander's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.

Account